Login / Signup

Cardiac Events After Standard of Care Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma.

Dae Hyun LeeAbhishek KumarTurab MohammedLauren C PeresMelissa AlsinaChristina A BachmeierBrandon BlueJason BrayerSanjay A ChandrasekharAriel F Grajales-CruzGabriel De AvilaHany ElmariahRawan G FaramandCiara Louise FreemanMichael D JainSushmita KhadkaFarhad KhimaniHien LiuTaiga NishihoriLaura B OswaldOmar Castaneda PuglianiniKenneth H ShainEric SmithRachid C BazFrederick L LockeGuilherme Henrique OliveiraMohammed AlomarDoris K Hansen
Published in: Blood advances (2023)
Ide-cel CAR-T for RRMM is associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity are associated with cardiac events post-BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS, although due to the small sample size, the power to detect an association was limited.
Keyphrases
  • cell therapy
  • multiple myeloma
  • left ventricular
  • stem cells
  • healthcare
  • acute lymphoblastic leukemia
  • mesenchymal stem cells
  • acute myeloid leukemia